Pfizer Looks Outside For Small Molecule Drug Discovery Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
With potential milestones and targets, PTC deal could be valued at over $1 billion.
You may also be interested in...
PTC Taps Genzyme’s Global Reach, Pocketbook In Ultra-orphan Licensing Deal
PTC124 offers new approach for treating lysosomal storage disorders central to Genzyme’s success, as well as other genetic diseases.
PTC Taps Genzyme’s Global Reach, Pocketbook In Ultra-orphan Licensing Deal
PTC124 offers new approach for treating lysosomal storage disorders central to Genzyme’s success, as well as other genetic diseases.
BioMarin Licenses UCSF Technology To Address Cause of Cystic Fibrosis
UCSF researcher Alan Verkman will have an ongoing role in lead optimization and development, BioMarin’s CEO tells “The Pink Sheet” DAILY.